{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:23:13Z","timestamp":1791274993525,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials failed to prove efficacy of mTOR inhibitor treatment. Here, we demonstrate that treatment with mTOR inhibitors result in the removal of negative feedback loops and up-regulates pro-proliferative phosphatidylinositol 3-kinase (PI3K)-Akt and PI3K-extracellular signal-regulated kinase (ERK) signaling in rat and mouse PKD models. Dual mTOR\/PI3K inhibition with NVP-BEZ235 abrogated these pro-proliferative signals and normalized kidney morphology and function by blocking proliferation and fibrosis. Our findings suggest that multi-target PI3K\/mTOR inhibition may represent a potential treatment for ADPKD.<\/jats:p>","DOI":"10.1038\/s41598-018-22938-x","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:48Z","timestamp":1522281648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Dual mTOR\/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease"],"prefix":"10.1038","volume":"8","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pejchinovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Castelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Watnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Arcaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Siwy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"22938_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","volume":"60","author":"PC Harris","year":"2009","unstructured":"Harris, P. C. & Torres, V. E. Polycystic kidney disease. Annu Rev Med 60, 321\u2013337 (2009).","journal-title":"Annu Rev Med"},{"issue":"1","key":"22938_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1755-8417-2-6","volume":"2","author":"A Boletta","year":"2009","unstructured":"Boletta, A. Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2(1), 6 (2009).","journal-title":"Pathogenetics"},{"issue":"12","key":"22938_CR3","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/hmg\/ddp149","volume":"18","author":"CS Bonnet","year":"2009","unstructured":"Bonnet, C. S. et al. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 18(12), 2166\u20132176 (2009).","journal-title":"Hum Mol Genet"},{"issue":"5","key":"22938_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.2011040340","volume":"23","author":"Z Novalic","year":"2012","unstructured":"Novalic, Z. et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 23(5), 842\u2013853 (2012).","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"22938_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363(9), 820\u2013829 (2010).","journal-title":"N Engl J Med"},{"issue":"3","key":"22938_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2009040421","volume":"21","author":"JM Shillingford","year":"2010","unstructured":"Shillingford, J. M., Piontek, K. B., Germino, G. G. & Weimbs, T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21(3), 489\u2013497 (2010).","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"22938_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz, G. & Budde, K. al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363(9), 830\u2013840 (2010).","journal-title":"N Engl J Med"},{"issue":"4","key":"22938_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000104818","volume":"30","author":"M Wu","year":"2007","unstructured":"Wu, M. et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30(4), 253\u2013259 (2007).","journal-title":"Kidney Blood Press Res"},{"issue":"9","key":"22938_CR9","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9), 3065\u20133074 (2008).","journal-title":"J Clin Invest"},{"issue":"18","key":"22938_CR10","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1002\/cncr.26011","volume":"117","author":"B Svejda","year":"2011","unstructured":"Svejda, B. et al. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1\/2 and AKT. Cancer 117(18), 4141\u20134154 (2011).","journal-title":"Cancer"},{"issue":"4","key":"22938_CR11","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1210\/me.2009-0328","volume":"24","author":"A Veilleux","year":"2010","unstructured":"Veilleux, A., Houde, V. P., Bellmann, K. & Marette, A. Chronic inhibition of the mTORC1\/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol Endocrinol 24(4), 766\u2013778 (2010).","journal-title":"Mol Endocrinol"},{"issue":"1","key":"22938_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2010.02.018","volume":"295","author":"K Zitzmann","year":"2010","unstructured":"Zitzmann, K. et al. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295(1), 100\u2013109 (2010).","journal-title":"Cancer Lett"},{"issue":"Suppl 6","key":"22938_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/ndt\/11.supp6.46","volume":"11","author":"N Gretz","year":"1996","unstructured":"Gretz, N. et al. Rat models of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 11(Suppl 6), 46\u201351 (1996).","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"22938_CR14","doi-asserted-by":"publisher","first-page":"F1597","DOI":"10.1152\/ajprenal.00430.2009","volume":"297","author":"M Wu","year":"2009","unstructured":"Wu, M. et al. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 297(6), F1597\u2013F1605 (2009).","journal-title":"Am J Physiol Renal Physiol"},{"issue":"22","key":"22938_CR15","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1128\/MCB.00217-10","volume":"30","author":"HW Kim","year":"2010","unstructured":"Kim, H. W. et al. Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D. Mol Cell Biol 30(22), 5406\u20135420 (2010).","journal-title":"Mol Cell Biol"},{"issue":"9","key":"22938_CR16","doi-asserted-by":"publisher","first-page":"C779","DOI":"10.1152\/ajpcell.00381.2013","volume":"306","author":"D Lu","year":"2014","unstructured":"Lu, D. & Insel, P. A. Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis. Am J Physiol Cell Physiol 306(9), C779\u2013C788 (2014).","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"22938_CR17","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/ijms16022320","volume":"16","author":"E Schinner","year":"2015","unstructured":"Schinner, E., Wetzl, V. & Schlossmann, J. Cyclic nucleotide signalling in kidney fibrosis. Int J Mol Sci 16(2), 2320\u20132351 (2015).","journal-title":"Int J Mol Sci"},{"issue":"3","key":"22938_CR18","first-page":"487","volume":"32","author":"M Pejchinovski","year":"2017","unstructured":"Pejchinovski, M. et al. Urinary peptidome analysis predicts the risk of end stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant 32(3), 487\u2013497 (2017).","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"22938_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.kint.2016.06.023","volume":"90","author":"J Klein","year":"2016","unstructured":"Klein, J. et al. Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney Int 90(5), 1045\u20131055 (2016).","journal-title":"Kidney Int"},{"issue":"5","key":"22938_CR20","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00280-011-1813-7","volume":"69","author":"L Berk","year":"2012","unstructured":"Berk, L. et al. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. Cancer Chemother Pharmacol 69(5), 1369\u20131377 (2012).","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"22938_CR21","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","volume":"10","author":"G Canaud","year":"2010","unstructured":"Canaud, G. et al. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant 10(7), 1701\u20131706 (2010).","journal-title":"Am J Transplant"},{"issue":"10","key":"22938_CR22","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","volume":"26","author":"C Tanaka","year":"2008","unstructured":"Tanaka, C. et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26(10), 1596\u20131602 (2008).","journal-title":"J Clin Oncol"},{"issue":"52","key":"22938_CR23","doi-asserted-by":"publisher","first-page":"22299","DOI":"10.1073\/pnas.0905152106","volume":"106","author":"SM Brachmann","year":"2009","unstructured":"Brachmann, S. M. et al. Specific apoptosis induction by the dual PI3K\/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106(52), 22299\u201322304 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"22938_CR24","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12), 1351\u20131356 (2008).","journal-title":"Nat Med"},{"issue":"3","key":"22938_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood-2009-07-235747","volume":"115","author":"AM Roccaro","year":"2010","unstructured":"Roccaro, A. M. et al. Dual targeting of the PI3K\/Akt\/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115(3), 559\u2013569 (2010).","journal-title":"Blood"},{"issue":"5","key":"22938_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mas.20205","volume":"28","author":"H Mischak","year":"2009","unstructured":"Mischak, H. et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. Mass Spectrom Rev 28(5), 703\u2013724 (2009).","journal-title":"Mass Spectrom Rev"},{"issue":"1","key":"22938_CR27","doi-asserted-by":"publisher","first-page":"F236","DOI":"10.1152\/ajprenal.00129.2010","volume":"300","author":"F Belibi","year":"2011","unstructured":"Belibi, F., Ravichandran, K., Zafar, I., He, Z. & Edelstein, C. L. mTORC1\/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol 300(1), F236\u2013F244 (2011).","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"22938_CR28","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3892\/ijo.2014.2505","volume":"45","author":"dG Moon","year":"2014","unstructured":"Moon, d. G. et al. NVP-BEZ235, a dual PI3K\/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 45(3), 1027\u20131035 (2014).","journal-title":"Int J Oncol"},{"issue":"20","key":"22938_CR29","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.1158\/1078-0432.CCR-11-0933","volume":"17","author":"N Jin","year":"2011","unstructured":"Jin, N., Jiang, T., Rosen, D. M., Nelkin, B. D. & Ball, D. W. Synergistic action of a RAF inhibitor and a dual PI3K\/mTOR inhibitor in thyroid cancer. Clin Cancer Res 17(20), 6482\u20136489 (2011).","journal-title":"Clin Cancer Res"},{"issue":"11","key":"22938_CR30","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/stem.521","volume":"28","author":"J Sunayama","year":"2010","unstructured":"Sunayama, J. et al. Crosstalk between the PI3K\/mTOR and MEK\/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28(11), 1930\u20131939 (2010).","journal-title":"Stem Cells"},{"issue":"12","key":"22938_CR31","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1097\/01.ASN.0000144204.01352.86","volume":"15","author":"KB Piontek","year":"2004","unstructured":"Piontek, K. B. et al. A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol 15(12), 3035\u20133043 (2004).","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"22938_CR32","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/nm1675","volume":"13","author":"K Piontek","year":"2007","unstructured":"Piontek, K., Menezes, L. F., Garcia-Gonzalez, M. A., Huso, D. L. & Germino, G. G. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 13(12), 1490\u20131495 (2007).","journal-title":"Nat Med"},{"issue":"1","key":"22938_CR33","doi-asserted-by":"publisher","first-page":"e87660","DOI":"10.1371\/journal.pone.0087660","volume":"9","author":"XS Ren","year":"2014","unstructured":"Ren, X. S. et al. Activation of the PI3K\/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat. PLoS ONE 9(1), e87660 (2014).","journal-title":"PLoS ONE"},{"key":"22938_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-8-38","volume":"8","author":"K Pollizzi","year":"2009","unstructured":"Pollizzi, K., Malinowska-Kolodziej, I., Stumm, M., Lane, H. & Kwiatkowski, D. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8, 38 (2009).","journal-title":"Mol Cancer"},{"issue":"3","key":"22938_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/bju.13415","volume":"118","author":"E Seront","year":"2016","unstructured":"Seront, E. et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int 118(3), 408\u2013415 (2016).","journal-title":"BJU Int"},{"issue":"6","key":"22938_CR36","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/0008-5472.CAN-13-1729","volume":"74","author":"A Lin","year":"2014","unstructured":"Lin, A. et al. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res 74(6), 1682\u20131693 (2014).","journal-title":"Cancer Res"},{"issue":"2","key":"22938_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.canlet.2014.12.015","volume":"357","author":"YH Chen","year":"2015","unstructured":"Chen, Y. H. et al. Dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett 357(2), 582\u2013590 (2015).","journal-title":"Cancer Lett"},{"issue":"5","key":"22938_CR38","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1158\/1078-0432.CCR-13-1607","volume":"20","author":"CR Gil del Alcazar","year":"2014","unstructured":"Gil del Alcazar, C. R. et al. Inhibition of DNA double-strand break repair by the dual PI3K\/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 20(5), 1235\u20131248 (2014).","journal-title":"Clin Cancer Res"},{"issue":"1","key":"22938_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1593\/neo.111512","volume":"14","author":"B Mukherjee","year":"2012","unstructured":"Mukherjee, B. et al. The dual PI3K\/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14(1), 34\u201343 (2012).","journal-title":"Neoplasia"},{"issue":"5","key":"22938_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mas.20205","volume":"28","author":"J Novak","year":"2009","unstructured":"Novak, J., Weissinger, E. M., Schanstra, J. P. & Dominiczak, A. F. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. Mass Spectrom Rev 28(5), 703\u2013724 (2009).","journal-title":"Mass Spectrom Rev"},{"issue":"4","key":"22938_CR41","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/prca.200900189","volume":"4","author":"H Mischak","year":"2010","unstructured":"Mischak, H. et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 4(4), 464\u2013478 (2010).","journal-title":"Proteomics Clin Appl"},{"issue":"1","key":"22938_CR42","first-page":"125","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B (Methodological) 57(1), 125\u2013133 (1995).","journal-title":"J Royal Stat Soc B (Methodological)"},{"issue":"5-6","key":"22938_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/prca.201400163","volume":"9","author":"M Pejchinovski","year":"2015","unstructured":"Pejchinovski, M. et al. Comparison of higher energy collisional dissociation and collision-induced dissociation MS\/MS sequencing methods for identification of naturally occurring peptides in human urine. Proteomics Clin Appl 9(5-6), 531\u2013542 (2015).","journal-title":"Proteomics Clin Appl"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22938-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22938-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22938-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T04:09:00Z","timestamp":1671595740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22938-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["22938"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-22938-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"24 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.M. is founder and co-owner of Mosaiques Diagnostics GmbH, who developed CE-MS technology. M.P. and J.S. are employees of Mosaiques Diagnostics GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5584"}}